Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing.

Competing Interests: RW curated, analysed, and validated the data and edited this Correspondence. MJ investigated and analysed the data. NC, AK, and NT contributed to data acquisition, administered the study, and curated the data. BS analysed and validated the data and edited this Correspondence. TM, VW, and ABA-N contributed to data acquisition. AO’C, MJA, GPC, and CPF contributed to data aquisition and edited the manuscript. AJD contributed to data acquisition, acquired funding, and edited the manuscript. DG supervised data analysis and edited the manuscript. SHL conceptualised, supervised, and administered the study; acquired, curated, analysed, and validated the data; wrote the original draft; and acquired funding. All authors reviewed the manuscript, had full access to the data, and were responsible for the decision to submit for publication. SHL has received speaker honoraria from AstraZeneca. MJA receives research funding from Pfizer. GPC receives research funding from Pfizer and participates in advisory boards for AstraZeneca and Pfizer. AJD receives research funding and honoraria from AstraZeneca and Janssen. CPF has received speaker and consultancy honoraria from Janssen and AstraZeneca. All other authors declare no competing interests. The databases with individual-level information used for this work are not publicly available due to personal data protection. Individual participant data that underlie the results reported in this Correspondence, after de-identification (ie, text, tables, figures, and appendices), and the study protocol will be shared on request to the corresponding author for individual participant data meta-analysis. De-identified participant data supporting the findings will be available on completion of the study on reasonable request to the corresponding author after approval by an independent review committee. Proposals can be submitted up to 12 months after completion of the study (ie, Jan 31, 2025). The study design and statistical analysis plan are included in the appendix (pp 14–15). The PROSECO study is funded by the Blood Cancer UK Vaccine Research Collaborative, which is led by Blood Cancer UK in partnership with Myeloma UK, Anthony Nolan, and the British Society for Haematology (21009), awarded to SHL and supported by a Cancer Research UK Advanced Clinician Scientist Fellowship to SHL (A27179), Cancer Research UK and National Institute for Health Research (NIHR) Southampton Experimental Cancer Medicine Centre awarded to AJD (A25141), NIHR Southampton Clinical Research Facility Southampton Research Biorepository, and NIHR Southampton Biomedical Research Centre. DG receives support from the NIHR Great Ormond Street Biomedical Research Centre. GPC receives support from the NIHR Oxford Biomedical Research Centre and Cancer Research UK Experimental Cancer Medicines Centre. MJA receives support from NIHR Leicester Biomedical Research Centre. The funding sources had no role in the writing of this Correspondence or decision to submit for publication. No pharmaceutical company or other agency has paid us to write this Correspondence. We acknowledge the contribution of other members listed within the appendix (p 16).